WHAT IS CLAIMED IS:

1. Use of a therapeutically effective amount of MK-0677 in the manufacture of a medicament for the treatment of growth hormone deficiency (GHD) in children known to have short stature and equivalent growth potential compared to rhGH,

wherein the therapeutically effective amount is 0.1-2.0 mg/kg/d and a child has equivalent growth potential compared to rhGH when the child has:

(i.) a peak serum GH ≥5 μg/L in response to a single oral dose of MK-0677; and,

(ii.) a baseline serum IGF-I of >30ng/mL.

2. The use of Claim 1, wherein a single 0.8 mg/kg/d dose of MK-0677 is to be administered orally.

3. The use of Claim 1, wherein at least one mini-tablets, comprising: MK-0677 is to be administered orally.

4. The use of Claim 3, wherein the mini-tablet, comprises: 2 mg of MK-0677.

5. The use of Claim 1, wherein the GHD is pediatric GHD.

6. The use of Claim 1, wherein MK-0677 is for to be administered orally with the assistance of a device capable of dispensing at least one MK-0677 mini-tablet.

7. Use of a therapeutically effective amount of MK-0677 in the manufacture of a medicament for the treatment of

GHD in children found from a theranostic test to have short stature and equivalent growth potential compared to rhGH;

wherein the therapeutically effective amount is 0.1-2.0 mg/kg/d and a child has equivalent growth potential compared to rhGH when the child has:

(i.) a peak serum GH ≥5 µg/L in response to a single oral dose of MK-0677; and,

(ii.) a baseline serum IGF-I of >30ng/mL.

8. The use of Claim 7, wherein a single, 0.8 mg/kg/d dose of MK-0677 is to be administered orally.

9. The use of Claim 7, wherein at least one mini-tablet[s], comprising: MK-0677 is to be administered orally.

10. The use of Claim 5, wherein the mini-tablet, comprises: 2 mg of MK-0677.

11. The use of Claim 7, wherein the therapeutically effective amount of MK-0677 is to be administered orally with the assistance of a device capable of dispensing at least one MK-0677 mini-tablet.

12. The use of Claim 7, wherein the GHD is pediatric GHD.

13. The use of Claim 7, wherein the children found from a ~~theranostic test~~ theranostic test to have short stature and equivalent growth potential compared to rhGH, comprises:

(i.) a peak serum GH of ≥5 µg/L in response to a single oral dose of MK-0677; and,

(ii.) a baseline serum IGF-I of >30ng/mL.

14. The use of Claim 13, wherein the single oral dose of MK-0677 is 0.8 mg/kg/d~~-~~.

15. The use of Claim 1, wherein the therapeutically effective amount is 0.8 mg/kg/d of MK-0677.

16. The use of Claim 1, wherein the therapeutically effective amount is 1.6 mg/kg/d of MK-0677.

17. The use of Claim 7, wherein the therapeutically effective amount is 0.8 mg/kg/d of MK-0677.

18. The use of Claim 7, wherein the therapeutically effective amount is 1.6 mg/kg/d of MK-0677.

19. The use of Claim 3, wherein the mini-tablet, comprises: 4 mg of MK-0677.

20. The use of Claim 9, wherein the mini-tablet, comprises: 4 mg of MK-0677.

21. The use of Claim 1, wherein the treatment is to be maintained for more than 6 months.

22. The use of Claim 1, ~~for~~wherein the treatment is to be maintained for at least 7 months.

23. The use of Claim 1, ~~for~~wherein the treatment is to be maintained until growth potential is exhausted.

24. The use of Claim 7, ~~for~~wherein the treatment is to be maintained for more than 6 months.

25. The use of Claim 7, ~~for~~wherein the treatment is to be maintained for at least 7 months.

26. The use of Claim 7, ~~for~~wherein the treatment is to be maintained until growth potential is exhausted.